🇺🇸 Peginterferon Alfa in United States

8,474 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 8,474

Most-reported reactions

1. Anaemia — 1,925 reports (22.72%)
2. Rash — 1,160 reports (13.69%)
3. Fatigue — 1,056 reports (12.46%)
4. Nausea — 1,017 reports (12%)
5. Pruritus — 607 reports (7.16%)
6. White Blood Cell Count Decreased — 603 reports (7.12%)
7. Decreased Appetite — 542 reports (6.4%)
8. Haemoglobin Decreased — 542 reports (6.4%)
9. Pyrexia — 521 reports (6.15%)
10. Depression — 501 reports (5.91%)

Source database →

Frequently asked questions

Is Peginterferon Alfa approved in United States?

Peginterferon Alfa does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Peginterferon Alfa in United States?

Third Affiliated Hospital, Sun Yat-Sen University is the originator. The local marketing authorisation holder may differ — check the official source linked above.